Trials / Conditions / Genital Neoplasms, Male

Genital Neoplasms, Male

16 registered clinical trials studyying Genital Neoplasms, Male — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 NCT06785636	Pathos AI, Inc.	Phase 1 / Phase 2
Recruiting	18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prost NCT06706921	VA Greater Los Angeles Healthcare System	Phase 4
Unknown	EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRP NCT05150236	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Phase 2
Completed	High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy NCT04461509	Alessandro D'Agnolo	Phase 2
Terminated	Trial of NanoPac Focal Therapy for Prostate Cancer NCT04221828	NanOlogy, LLC	Phase 2
Terminated	P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947	Poseida Therapeutics, Inc.	Phase 1
Completed	Health Gatherings - For Your Health After Cancer NCT03344757	University of Miami	N/A
Terminated	Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors NCT02499952	Nasser Hanna, M.D.	Phase 2
Terminated	Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer NCT02606123	ESSA Pharmaceuticals	Phase 1 / Phase 2
Active Not Recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Inj NCT02266745	Promontory Therapeutics Inc.	Phase 2
Terminated	Protection of Rectum From High Radiation Doses Using a Spacer NCT01918605	University of Oulu	N/A
Active Not Recruiting	MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness NCT01464216	Oslo University Hospital	—
Terminated	A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer NCT00672009	Cedars-Sinai Medical Center	Phase 2
Completed	Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma NCT00210041	Institut Claudius Regaud	Phase 2
Completed	Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy NCT01316458	Novartis Pharmaceuticals	Phase 2
Approved For Marketing	Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer NCT01217697	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	—